Giacobbi V, Trivin C, Lawson-Body E, Fonseca M, Souberbielle J-C, Brauner R
Université René-Descartes and Pediatric Endocrinology Unit, Fondation-Hôpital Saint-Joseph, Paris, France.
Horm Res. 2003;60(6):272-6. doi: 10.1159/000074244.
Idiopathic extremely short stature probably has several causes.
To evaluate the influence of each parent's height on clinical-biological features.
57 patients without intrauterine growth retardation seen at 7.9 +/- 0.4 years for height < or = -3 SD were classified according to the difference between their target height and actual height: < 2 SD in familial short stature (FSS, n = 28) and >2 SD in non-FSS (n = 29).
Height decreased from -0.5 +/- 0.1 SD at birth to -2 +/- 0.2 SD at 1 year and -2.7 +/- 0.1 SD at 3 years, but the changes in the two groups were similar. FSS children were shorter than non-FSS children both at birth (p = 0.03) and as adults after growth hormone (GH) treatment (p < 0.05), but their plasma insulin-like growth factor I concentrations and GH peaks were similar. The FSS children fathers' heights were more frequently below -2 SD (64%) than the mothers' heights (35%) and were correlated with height at first evaluation (p < 0.05). For the whole population, the mothers' heights were correlated with birth weight (p < 0.05) and with height at first evaluation (p < 0.03).
This study confirms the influence of the mother's height on birth weight and shows how of the father's height influences idiopathic extremely short stature.
特发性极度矮小可能有多种原因。
评估父母身高对临床生物学特征的影响。
57例无宫内生长迟缓的患者,在7.9±0.4岁时身高≤ -3标准差,根据其靶身高与实际身高的差异进行分类:家族性矮小(FSS,n = 28)中差异< 2标准差,非FSS(n = 29)中差异> 2标准差。
身高从出生时的-0.5±0.1标准差降至1岁时的-2±0.2标准差和3岁时的-2.7±0.1标准差,但两组的变化相似。FSS儿童在出生时(p = 0.03)和生长激素(GH)治疗后的成年期均比非FSS儿童矮(p < 0.05),但其血浆胰岛素样生长因子I浓度和GH峰值相似。FSS儿童父亲的身高低于-2标准差的频率(64%)高于母亲的身高(35%),且与首次评估时的身高相关(p < 0.05)。对于总体人群,母亲的身高与出生体重相关(p < 0.05)以及与首次评估时的身高相关(p < 0.03)。
本研究证实了母亲身高对出生体重的影响,并表明父亲身高如何影响特发性极度矮小。